Adell Harriman & Carpenter Inc. Boosts Position in Eli Lilly and Company $LLY

Adell Harriman & Carpenter Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 4.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 15,022 shares of the company’s stock after acquiring an additional 686 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in Eli Lilly and Company were worth $11,711,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Amalgamated Bank increased its holdings in shares of Eli Lilly and Company by 1.5% in the second quarter. Amalgamated Bank now owns 172,735 shares of the company’s stock valued at $134,652,000 after purchasing an additional 2,573 shares during the period. Savvy Advisors Inc. lifted its position in Eli Lilly and Company by 44.8% during the second quarter. Savvy Advisors Inc. now owns 6,889 shares of the company’s stock worth $5,370,000 after buying an additional 2,132 shares during the period. Fortune 45 LLC increased its stake in Eli Lilly and Company by 15.2% during the second quarter. Fortune 45 LLC now owns 605 shares of the company’s stock worth $472,000 after acquiring an additional 80 shares during the last quarter. MeadowBrook Investment Advisors LLC grew its stake in shares of Eli Lilly and Company by 92.9% in the second quarter. MeadowBrook Investment Advisors LLC now owns 600 shares of the company’s stock valued at $468,000 after buying an additional 289 shares in the last quarter. Finally, Assetmark Inc. grew its stake in Eli Lilly and Company by 16.1% during the 2nd quarter. Assetmark Inc. now owns 52,218 shares of the company’s stock valued at $40,706,000 after purchasing an additional 7,240 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.1%

Shares of LLY opened at $810.78 on Thursday. The business’s 50 day simple moving average is $775.02 and its 200-day simple moving average is $770.34. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $767.37 billion, a P/E ratio of 52.99, a PEG ratio of 1.22 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 39.22%.

Analyst Ratings Changes

Several research firms recently commented on LLY. Berenberg Bank restated a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. BMO Capital Markets raised their target price on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a research report on Sunday, August 17th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $938.61.

Insider Activity

In related news, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. The trade was a 0.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.